KT-621

· Kymera Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for KT-621, covering 2025-10-02 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis [Phase 2]